Maatman T J
Department of Urology, Metropolitan Hospital, Grand Rapids.
J Urol. 1989 Jun;141(6):1378-80. doi: 10.1016/s0022-5347(17)41313-9.
Serial serum prostate specific antigen levels were obtained every 4 hours during a 24-hour interval from 8 men with stage D adenocarcinoma of the prostate. No therapeutic or diagnostic manipulations occurred during sample procurement, so that the amount of fluctuation of serum prostate specific antigen levels that can be expected in these patients could be determined. The coefficient of variation for each man ranged from 1.16 to 10.94 per cent, which was not statistically higher than the expected 4.39 and 11.44 per cent coefficient of variation determined with a control sample. The maximum percentage variations above and below the mean were 19.3 and 17.7 per cent, respectively. The average percentage variation in all patients was within 7.6 per cent greater than and 7.6 per cent less than the mean value of prostate specific antigen. Thus, prostate specific antigen appears to be a reliable tumor marker because there is minimal random fluctuation when serial levels are obtained in men with advanced prostate cancer. Based on these findings certain guidelines are suggested.
在24小时内，对8名患有D期前列腺腺癌的男性每4小时采集一次血清前列腺特异性抗原水平。在样本采集过程中未进行任何治疗或诊断操作，以便确定这些患者血清前列腺特异性抗原水平可能出现的波动量。每名男性的变异系数在1.16%至10.94%之间，在统计学上并不高于用对照样本确定的预期变异系数4.39%和11.44%。高于和低于平均值的最大百分比变化分别为19.3%和17.7%。所有患者的平均百分比变化在高于前列腺特异性抗原平均值7.6%和低于平均值7.6%的范围内。因此，前列腺特异性抗原似乎是一种可靠的肿瘤标志物，因为在晚期前列腺癌男性中连续检测水平时随机波动极小。基于这些发现提出了某些指导原则。
